ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / VERU / forecast
SCYX (28) NSRX (26) ATHE (45) GRDX (39) ⌘ Pro Terminal →

Veru Inc. (VERU) 12-Month Stock Forecast & Price Target Cone

$2.16 -1.37% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.15

Veru Inc. (VERU) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $37.3M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on VERU Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is VERU stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Veru Inc. (NASDAQ: VERU) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $2.16 (-1.37% 1D, market cap $37.3M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, VERU ranks #808 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does VERU compare to SCYX and NSRX in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), VERU carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, SCYX (SCYNEXIS Inc.) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $37.5M) and NSRX (Nasus Pharma Ltd.) posts a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $36.0M). Among the 5-stock peer group, VERU leads on earnings multiple (N/A) while GRDX leads on capital efficiency (-20.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for VERU?
▼

Per VERU's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0000863894), Veru Inc. generated $69.3M in revenue (+310.4% YoY), -$22.7M in net income, and -$30.0M in free cash flow against $47.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $2.15 (-0.44%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510030
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D
Cash (4)Whales (3)SEC (10)Macro (8)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-12.5% Base Target
$8 Bull$2 Base$1 Bear
📬 FREE VERU RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for VERU)Realized 20D OHLCV Swing Band: ±11.5%
Deterministic 5-Pillar Attribution (30/100 Composite)
🔍 WHY VERU SCORES 30/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (33% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (27% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 41 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
38
Grade E$2.19+8.7% Next Q
Q2 (-2Q)
35
Grade E$2.38-4.2% Next Q
Q3 (-1Q)
33
Grade E$2.28-5.3% Next Q
Current
30
Grade E$2.16-9.6% Hist 90D α
Trajectory: E (38) → E (30)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a VERU Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While VERU currently carries a cautious 30/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.45) and Max Pain ($2.27) forces dealer call-delta covering toward $7.70.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $VERU• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “VERU Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”
YES 30%NO 70%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your VERU Position Size: $10,000

Shares at $2.16: 4629.6 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $1.47
$6,806
$-3,194 (-31.9%)
12M Consensus BaseTarget $1.89
$8,750
$-1,250 (-12.5%)
12M Bull Case BreakoutTarget $7.70
$35,648
+$25,648 (+256.5%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 9
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$274%A
Goldman SachsSector Coverage LeadUNDERPERFORM$769%B
JP MorganUS Large-Cap ResearchSELL$258%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring VERU)

  • ✓Walkthrough of VERU's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
VERU // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -4.00%🛡️ HOLDING TREND SUPPORT
2026-11-03O $2.23H $2.23L $2.16C $2.16VOL 79.0K
RES: $2.68SUP: $2.16SMA50: $2.45SMA200: $2.49
$7.70$6.17$4.64$3.11$1.57RES $2.68SUP $2.16$2.162026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

VERU Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 VERU Butterfly Map → + Track VERU →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +310.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on VERU today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for VERU. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for VERU today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (VERU)

Health Care Rank #808 of 1015 ⚔️ SCYX vs VERU Full Matrix →

1. Head-to-Head Health Care Peer Comparison (VERU vs. SCYX, NSRX, ATHE, GRDX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Veru Inc. (VERU) ranks #808 by composite RQD confidence (30/100, grade E) and #775 by equity capitalization ($37.3M). Within this direct 5-issuer industry benchmark cohort, VERU leads on earnings valuation at N/A trailing P/E, while GRDX leads on capital efficiency and profitability with -20.0% ROIC and -30.0% gross margin. ATHE currently holds the highest overall quantitative score in the immediate peer group at 45/100 (D) compared with VERU at 30/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
VERU ACTIVE
Veru Inc.
E 30/100 — — -35.0% -1.37% $37.3M Benchmark Subject
SCYX
SCYNEXIS Inc.
E 28/100 — — -35.0% +1.06% $37.5M /scyx-vs-veru →
NSRX
Nasus Pharma Ltd.
E 26/100 — — -35.0% +4.21% $36.0M /nsrx-vs-veru →
ATHE
Alterity Therapeutics Limited
D 45/100 — — — -3.24% $39.3M /athe-vs-veru →
GRDX
GridAI Technologies Corp.
D- 39/100 — -30.0% -20.0% -3.43% $35.4M /grdx-vs-veru →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-09-30 • CIK 0000863894 ↗

In its most recent audited fiscal period (FY2025, filed 2025-09-30), Veru Inc. (VERU) reported GAAP revenue of $69.3M (+310.4% vs. FY2024 revenue of $16.9M , and +325.2% cumulative change since FY2023) , GAAP net income of -$22.7M, operating cash flow of -$30.0M, and free cash flow of -$30.0M (-37.6% YoY). On the balance sheet, VERU closed FY2025 with $47.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-09-30 $69.3M -$22.7M -$30.0M -$30.0M $47.6M —
FY2024 (FY) 2024-09-30 $16.9M -$37.8M -$21.7M -$21.8M $39.8M —
FY2023 (FY) 2023-09-30 $16.3M -$93.2M -$88.0M -$88.0M — —

3. VERU Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is VERU stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Veru Inc. (NASDAQ: VERU) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $2.16 (-1.37% 1D, market cap $37.3M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, VERU ranks #808 in composite RQD confidence.

How does VERU compare to SCYX and NSRX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), VERU carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, SCYX (SCYNEXIS Inc.) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $37.5M) and NSRX (Nasus Pharma Ltd.) posts a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $36.0M). Among the 5-stock peer group, VERU leads on earnings multiple (N/A) while GRDX leads on capital efficiency (-20.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for VERU?

Per VERU's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0000863894), Veru Inc. generated $69.3M in revenue (+310.4% YoY), -$22.7M in net income, and -$30.0M in free cash flow against $47.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is VERU trading relative to its 50-day, 200-day, and 52-week technical levels?

VERU last traded at $2.16 (-1.37% on volume of 249,941 shares), positioning the stock -11.84% below its 50-day simple moving average ($2.45) and -13.25% below its 200-day simple moving average ($2.49). Across its 52-week range of $2.05 to $7.33, VERU sits at the 2.1% percentile with a 14-day RSI of 41.0 (NEUTRAL RANGE) and an implied next-earnings move of ±11.5% ($1.91 to $2.41).

Direct Sub-Reports: VERU RQD Cockpit VERU 12M Forecast VERU Earnings & Move VERU Dividends & DRIP VERU Insiders & 13F VERU Whale Options VERU Profit Sankey VERU News & Why
ROARABLE RATING BRIEF • RQD 30/100 (E) ✓ SEC XBRL & RQD VERIFIED

VERU — Veru Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-09-30

1. Roarable Rating Brief: What This Means to a Prospective Investor

Veru Inc. (VERU) earns a live Roarable RQD composite score of 30/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $2.16 (-1.37% 1D, market capitalization $37.3M).

  • Fundamental Cash Engine (4/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Revenue is reported in the SEC financials for FY 2023 and FY 2024 and is — for FY 2025, but the source does not identify the revenue sources.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-09-30), Veru Inc. (VERU) reported $69.3M in annual revenue (up from $16.9M in FY2024, +310.4% YoY) and -$22.7M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($16.3M revenue, -$93.2M net income) through FY2025, VERU scaled operating cash flow to -$30.0M and free cash flow to -$30.0M, backed by $47.6M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 30/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 4/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $2.05 – $7.33 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Investors should note that the absence of mapped links means this brief cannot identify supplier or customer ripple effects.

  • Key Question #1: Can VERU sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $69.3M and free cash flow of -$30.0M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is VERU's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

VERU Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Veru Inc. (VERU) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to VERU Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

VERU Bull vs. Bear Conversation Board — What's Your Call at $2.16?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON VERU 🐻 33% BEARISH CONVICTION
1. Pick Your Side on VERU:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
AL AlphaFlow_Cap RQD DEBATE OPENER • Verified $100K Arena Trader 🐂 BULLISH 🎯 Target: $2.69 (+22.8%)
📌 Pinned Debate

Reported cash of $33.0M in FY 2025 and a price-level news item referencing upcoming obesity trial data give the stock a possible cataly

The street is overcomplicating Veru Inc. (VERU). Reported cash of $33.0M in FY 2025 and a price-level news item referencing upcoming obesity trial data give the stock a possible catalyst path.. With an RQD score of 30/100 (E) and Forensic Balance Sheet at 10/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $2.37.

VolSurface_Trader 🐂 BULL

@ForensicBear Shorting a 3/20 institutional whale-flow stock at $2.19 is dangerous when funds are rotating into Health Care.

FO ForensicBear RQD DEBATE OPENER • 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $1.73 (-21.0%)
Spot @ $2.19

A ROIC of -35%, FCF of -$30.0M in FY 2025, and an RQD score of 30 (E) show persistent cash burn with weak forensic and institutional su

A ROIC of -35%, FCF of -$30.0M in FY 2025, and an RQD score of 30 (E) show persistent cash burn with weak forensic and institutional support.. Look at the math on VERU: paying current EV/EBITDA multiples for -35.0% ROIC and 0.0% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $1.93 before getting long.

LIVE TAPE